派博傳思國際中心

標題: Titlebook: Combination Therapy In Dyslipidemia; Maciej Banach Book 2015 Springer International Publishing Switzerland 2015 Alirocumab.Anacetrapib.Apo [打印本頁]

作者: 雜技演員    時間: 2025-3-21 18:56
書目名稱Combination Therapy In Dyslipidemia影響因子(影響力)




書目名稱Combination Therapy In Dyslipidemia影響因子(影響力)學科排名




書目名稱Combination Therapy In Dyslipidemia網絡公開度




書目名稱Combination Therapy In Dyslipidemia網絡公開度學科排名




書目名稱Combination Therapy In Dyslipidemia被引頻次




書目名稱Combination Therapy In Dyslipidemia被引頻次學科排名




書目名稱Combination Therapy In Dyslipidemia年度引用




書目名稱Combination Therapy In Dyslipidemia年度引用學科排名




書目名稱Combination Therapy In Dyslipidemia讀者反饋




書目名稱Combination Therapy In Dyslipidemia讀者反饋學科排名





作者: 積云    時間: 2025-3-21 20:39
978-3-319-36721-7Springer International Publishing Switzerland 2015
作者: entreat    時間: 2025-3-22 02:20

作者: fixed-joint    時間: 2025-3-22 07:27
Keynes and the Cambridge Economics Schoolding dietary plant sterols [1]. Both dietary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol concentrations. Ezetimibe lowers plasma cholesterol by decreasing cholesterol absorption in the small intestine.
作者: Prologue    時間: 2025-3-22 09:48

作者: 點燃    時間: 2025-3-22 15:25

作者: 點燃    時間: 2025-3-22 17:08

作者: glamor    時間: 2025-3-22 22:25

作者: laparoscopy    時間: 2025-3-23 04:44
Maciej BanachAddresses a gap left by the latest dyslipidemia management guidelines.Current and comprehensive discussion of options for combination therapy of dyslipidemia.Contributions from an internationally accl
作者: 表被動    時間: 2025-3-23 08:53

作者: RACE    時間: 2025-3-23 13:26
Statins and Fibrates: Should They Be Recommended?,idual risk reducing, fibrates seem to be a very important alternative, especially for patients with atherogenic dyslipidaemia, which might be often observed in patients with diabetes and metabolic syndrome.
作者: 包裹    時間: 2025-3-23 17:14

作者: 擔憂    時間: 2025-3-23 19:07
https://doi.org/10.1007/978-3-031-35955-2(LDL-C) in order to reduce risk for acute cardiovascular events in both the primary and secondary prevention settings [1–3]. There is growing consensus that when it comes to LDL-C management, lower is better with no apparent lower limit that is discernible from current evidence, i.e., there is great
作者: BAIL    時間: 2025-3-24 01:50

作者: 套索    時間: 2025-3-24 02:51

作者: foliage    時間: 2025-3-24 09:59

作者: 脆弱吧    時間: 2025-3-24 13:09
https://doi.org/10.1057/9781403932860 However, despite their lipid lowering and cardioprotective effects, substantial residual cardiovascular risk persists in some patients taking statins, particularly in some subgroups, such as those with atherogenic dyslipidemia, i.e., high TG and low HDL. There has been significant controversy regar
作者: antiquated    時間: 2025-3-24 15:17

作者: RECUR    時間: 2025-3-24 22:02

作者: upstart    時間: 2025-3-24 23:45
https://doi.org/10.1007/978-1-349-20920-0om birth and the occurrence of premature cardiovascular disease and myocardial infarction. ADH is determined by defects in genes encoding for proteins involved in the metabolism of LDL, including ., . and .. Carrying these mutations results in the exposure to high levels of LDL-C from birth and the
作者: 鎮(zhèn)壓    時間: 2025-3-25 04:41

作者: 決定性    時間: 2025-3-25 10:34

作者: Offstage    時間: 2025-3-25 14:20
https://doi.org/10.1057/9780230117501tage of these patients, present-day pharmacotherapy, consisting of statins alone or in combination with other lipid-modifying medications, is unable to sufficiently reduce plasma cholesterol levels..Since the late 1970s, simple plasma exchange or the more selective lipoprotein apheresis (LA) therapy
作者: 珠寶    時間: 2025-3-25 17:01

作者: neutrophils    時間: 2025-3-25 20:00
Bembibre to Cacabelos and Villafranca,ed “a strategy to reduce cardiovascular disease by more than 80 %” by simultaneously addressing four cardiovascular risk factors regardless of pretreatment levels in a low-risk population. They stated, “the polypill strategy could largely prevent heart attacks and strokes if taken by everyone aged 5
作者: filicide    時間: 2025-3-26 01:23

作者: 諂媚于性    時間: 2025-3-26 04:50

作者: 震驚    時間: 2025-3-26 08:58
Book 2015d sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtil
作者: 厭煩    時間: 2025-3-26 15:46

作者: watertight,    時間: 2025-3-26 18:54

作者: Costume    時間: 2025-3-26 23:37
https://doi.org/10.1057/9781403932860or prevention of adverse cardiovascular outcomes and treatment of derangements in lipid serologies. Current guidelines and recommendations support their regular integration into the diet and supplementation for those with severe hypertriglyceridemia as adjunct therapy. Emerging data suggests that OM
作者: occurrence    時間: 2025-3-27 02:08

作者: MAZE    時間: 2025-3-27 06:51
https://doi.org/10.1007/978-1-349-20920-0rol-lowering drugs, especially subjects carrying mutations that drastically reduce the expression of hepatic LDLR. Thus, the need to find out new drugs directed to different targets led to the development of lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme playin
作者: 與野獸博斗者    時間: 2025-3-27 09:46
A Condition of England Minister,al trials have shown that these nutraceuticals have an additive effect to statins, allowing to reduce the doses of statins without decreasing the results in terms of effectiveness in reducing total and LDL-cholesterol and significantly limiting side effects..The results of the studies carried out ha
作者: 態(tài)度暖昧    時間: 2025-3-27 15:29

作者: evanescent    時間: 2025-3-27 20:16
The History of the East India Company II: ,,he practical issues of combined antihypertensive and lipid-lowering therapy, including adherence, cost-effectiveness, and effect of complementary therapy as well as the future of integrated management.
作者: follicular-unit    時間: 2025-3-27 22:11

作者: 天賦    時間: 2025-3-28 02:48

作者: esculent    時間: 2025-3-28 06:21
Statins and Niacin: The End of Residual Risk Therapy?,se in serious adverse effects. More specifically, apart from flushing, niacin was associated with increased incidence of new-onset diabetes and with a higher risk of all-cause mortality. As a result, niacin is no longer on the market in many countries.
作者: anarchist    時間: 2025-3-28 11:20
The Role of Omega-3 Fatty Acids in Dyslipidemias,or prevention of adverse cardiovascular outcomes and treatment of derangements in lipid serologies. Current guidelines and recommendations support their regular integration into the diet and supplementation for those with severe hypertriglyceridemia as adjunct therapy. Emerging data suggests that OM
作者: CLOWN    時間: 2025-3-28 15:37

作者: 激勵    時間: 2025-3-28 19:39
Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?,rol-lowering drugs, especially subjects carrying mutations that drastically reduce the expression of hepatic LDLR. Thus, the need to find out new drugs directed to different targets led to the development of lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme playin
作者: Jubilation    時間: 2025-3-29 00:46
Statins and Nutraceuticals/Functional Food: Could They Be Combined?,al trials have shown that these nutraceuticals have an additive effect to statins, allowing to reduce the doses of statins without decreasing the results in terms of effectiveness in reducing total and LDL-cholesterol and significantly limiting side effects..The results of the studies carried out ha
作者: 無聊的人    時間: 2025-3-29 03:39
Lipid-Lowering Therapy and Apheresis: Indications and Outcomes,ks depending on the severity of the patient’s disease and lipoprotein levels. Adverse reactions, though rare, are typical for other apheresis procedures. Due to the sophistication of the procedure, cost, and time commitment, presently only about 3,000 patients worldwide and 550 patients in North Ame
作者: Climate    時間: 2025-3-29 08:00

作者: aptitude    時間: 2025-3-29 15:26
The Cardiovascular Polypill in the Prevention of Cardiovascular Disease,sease. It was argued that a large proportion of the population would be medicalized unnecessarily, inducing a sense of protection and deflecting attention from healthy behaviors. Although this strategy raised high hopes that a polypill-based treatment could reduce the incidence of atherosclerotic ca
作者: 紳士    時間: 2025-3-29 19:22

作者: decode    時間: 2025-3-29 23:08

作者: 高貴領導    時間: 2025-3-30 01:13

作者: 虛弱    時間: 2025-3-30 05:58

作者: Condense    時間: 2025-3-30 11:30

作者: 知道    時間: 2025-3-30 14:35

作者: aviator    時間: 2025-3-30 16:52

作者: 碳水化合物    時間: 2025-3-30 22:22
Statins and Mipomersen: Mechanisms of Action and Patient Tolerability,gnificant challenge, particularly in severe, inherited hypercholesterolaemia. High-intensity statin therapy can be associated with adverse outcomes, most notably myalgia, and does not frequently result in the attainment of therapeutic levels of low-density lipoprotein (LDL) cholesterol and apolipopr
作者: Injunction    時間: 2025-3-31 01:12

作者: 侵略者    時間: 2025-3-31 05:06
Other Possible Drug Combinations for Dyslipidemia,ts have been successfully developed and introduced for LDL-C lowering, ezetimibe as a cholesterol absorption inhibitor being the exception [1]. Other promising lipid lowering agents such as fibrates and niacin have failed to provide mortality benefits in large clinical trials and are only used in se
作者: garrulous    時間: 2025-3-31 13:09
Statins and Nutraceuticals/Functional Food: Could They Be Combined?,of the leading causes of death in developed countries..Therefore, an effective treatment to reduce high cholesterol is necessary: statins have proved to be the gold standard among lipid-lowering drugs, but at the cost of many unpleasant side effects..At the same time, many nutraceuticals or function
作者: 洞察力    時間: 2025-3-31 14:59

作者: Basal-Ganglia    時間: 2025-3-31 19:27
Combination of Lipid-Lowering Agents with Antihypertensive Drugs: A Joint Fight Against the Two Mosa is common, particularly among older persons and those with diabetes and cardiovascular disease (CVD). When hypertension is accompanied by dyslipidemia, the combined risk for future CVD is substantial. Therefore, many studies have examined the effect of combined therapy for hypertension and dyslipi
作者: OTHER    時間: 2025-3-31 23:55





歡迎光臨 派博傳思國際中心 (http://www.pjsxioz.cn/) Powered by Discuz! X3.5
宝清县| 大姚县| 磴口县| 文化| 应城市| 延吉市| 潮州市| 布拖县| 金塔县| 罗山县| 莆田市| 宣恩县| 东至县| 文水县| 玛纳斯县| 阳泉市| 翁牛特旗| 察雅县| 徐水县| 湘阴县| 六枝特区| 高密市| 清原| 安康市| 孟州市| 临夏市| 宜阳县| SHOW| 新密市| 日喀则市| 大安市| 咸宁市| 神木县| 左权县| 蚌埠市| 南雄市| 宁乡县| 顺昌县| 漳平市| 体育| 嫩江县|